- Home
- EBS
as 11-08-2024 12:33pm EST
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 459.6M | IPO Year: | 2006 |
| Target Price: | $14.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.42 - $15.10 | Next Earning Date: | 11-06-2024 |
| Revenue: | $1,125,500,000 | Revenue Growth: | 2.05% |
| Revenue Growth (this year): | 6.83% | Revenue Growth (next year): | 2.50% |
Latest Emergent Biosolutions Inc. News
EBS Breaking Stock News: Dive into EBS Ticker-Specific Updates for Smart Investing
Benzinga
a day ago
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
MT Newswires
a day ago
Top Premarket Gainers
Zacks
a day ago
New Strong Buy Stocks for November 7th
Motley Fool
a day ago
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript
Zacks
2 days ago
Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates
Associated Press Finance
2 days ago
Emergent Biosolutions: Q3 Earnings Snapshot
GlobeNewswire
2 days ago
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
GlobeNewswire
2 days ago
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
Compare EBS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EBS Emergent Biosolutions Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.